Cross-Sector entity
Of the tracked stories, 2 of 2 also mention Amgen, the most common co-covered peer. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category. Each carries 132 original sources on average.
2 verified stories tracked
Last mentioned: Jul 16, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Amgen, the most common co-covered peer. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category. Each carries 132 original sources on average. We currently track 2 Cross-Sector stories that mention Regeneron, all published on July 16, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Regeneron. Shared-story counts are live from our verified record — not editorial picks.
FDA Approves Lipfendra
The FDA approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, for adults with hypercholesterolemia including inherited forms, based on Phase 3 CORALreef trials showing 56-59% LDL-C reduction.
The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol.
Merck won FDA approval for Lipfendra, a small-molecule oral PCSK9 inhibitor that achieved 56-59% LDL-C reductions in Phase 3. This breakthrough in oral delivery challenges the dominance of injectable biologics from Amgen and Sanofi/Regeneron.
Source: mix969.iheart.com · rock1053.iheart.com
